Switzerland-based pharmaceutical company, Acino has entered into a strategic partnership with Saudi Arabia’s Batterjee Pharma in order to support the Kingdom’s Health Sector Transformation Program, which was launched as part of National Vision 2030.
According to the statement, “Working with Batterjee, Acino will further its commitment to deliver enhanced access to high-quality essential medicines for patients and healthcare providers.”
Fahad Al Otaibi Country Manager Acino- Saudi Arabia
“Acino is committed to advancing the development of healthcare across Saudi Arabia, by accelerating access to high-quality medicines that patients and the government can trust and value. Our expansion in the Kingdom signals our commitment to this end, and collaboration with organizations like Batterjee is an important step in that journey. Together, we shall enhance patient services and promote higher standards, working with passion and skill towards better outcomes in care that lay the foundation for a more prosperous society.”
Acino’s agreement with Batterjee Pharma will deliver products in two stages. Acino’s anti-constipation medicines will be available later this year, and its gastro and gastroesophageal reflux disease (GERD) medicines will be available by 2024, as per the statement.
HE Abdullah Al Masoud, Saudi Commercial Attaché to Switzerland stated that, “Partnerships like these will contribute to the Saudi Vision 2030 and the Kingdom’s Health Sector Transformation goals that focus on quality, care, and optimization of treatment outcomes.”
Mr. Mohammed Batterjee, General Manager, Batterjee Pharma said that, “This agreement between Batterjee Pharma and Acino aligns closely with the government’s Health Sector Transformation Program and its wider aspirations for the betterment of Saudi society.”
“Our licensing agreement will accelerate Saudi patients’ access to the medicines they need to live full and fulfilling lives. We are proud to stand with Acino in pursuit of this vision,” Mr. Batterjee added.
